<DOC>
	<DOCNO>NCT01199393</DOCNO>
	<brief_summary>The investigator want research whether genetic polymorphism drug-metabolizing enzyme use predict chemotherapeutic outcome patient metastatic breast cancer .</brief_summary>
	<brief_title>Genetic Polymorphisms Predict Chemotherapeutic Outcomes Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>1 . Patients evaluation On patient complete clinical history physical examination perform , include routine hematology biochemistry analysis . Hematology biochemistry analysis repeat end cycle . Toxicity classify accord WHO criteria cycle patient . Response assess two cycle chemotherapy every two cycle thereafter , use Response Evaluation Criteria Solid Tumor Group ( RECIST ) guideline . 2 . Sample collection SNP genotyping Venous blood ( 4 ml ) collect subject place tube contain EDTA . Genomic DNA isolate DNA Blood isolation kit.Genotypes perform PCR-RFLP , PCR-DHPLC PCR-direct sequencing , etc . 3 . Statistical Analysis x2 test use summarize association response adverse event chemotherapy genetic polymorphism .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Histologically confirm metastatic breast cancer Female An Eastern Cooperative Oncology Group ( ECOG ) performance status 02 At least one measurable lesion Normal cardiac , hepatic , renal bone marrow function Life expectancy â‰¥3 month Discontinuity previous chemotherapy minimum 4 week Central nervous system metastases Serious uncontrolled concurrent medical illness History malignancy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>breast neoplasm</keyword>
	<keyword>drug therapy</keyword>
	<keyword>polymorphism</keyword>
	<keyword>gene</keyword>
</DOC>